Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Anthrasil Market Forecast: What Value Will The Market Reach By 2030?
Development during the historic period can be ascribed to government biodefense initiatives, the clinical success of immune globulin therapy, the absence of alternative toxin neutralizers, national emergency preparedness programs, and regulatory emergency approvals.
Expected growth throughout the forecast period is driven by sustained funding for public health readiness, the enlargement of biodefense reserves, an increasing emphasis on quickly neutralizing toxins, advancements in processing plasma-derived products, and enduring government procurement contracts.
Key trends projected for the forecast period include a rising adoption of anthrax immune globulin treatments, the expansion of combination therapy protocols, increased strategic accumulation of immune globulins, an elevated focus on toxin neutralization therapies, and improved management strategies for anthrax across pediatric and adult populations.
Get A Free Sample Report With In-Depth Market Insights:
Anthrasil Market Demand Drivers Opening New Revenue Streams
The rising occurrence of anthrax infections is anticipated to drive the expansion of the anthrasil market in the future. These infections stem from the bacterium Bacillus anthracis and can manifest via dermal contact, breathing in spores, or consumption, resulting in serious symptoms dependent on the exposure pathway. The growing incidence of anthrax infections is linked to elements like heightened exposure to sick animals, insufficient oversight from veterinarians, and socioeconomic obstacles that impede successful disease control and prophylaxis. A higher frequency of anthrax infections leads to increased utilization of anthrasil, given that more cases require potent therapies to deliver prompt passive immunity and enhance survival outcomes. For example, a report released in December 2023 by the World Health Organization (WHO), a health body located in Switzerland, indicated that suspected anthrax cases in Zambia climbed from 42 between September 2022 and January 2023 to 684 by November 20, 2023. This included four deaths (0.6% CFR), affecting 44 districts across nine of the country’s ten provinces. Consequently, the escalating prevalence of anthrax infections is propelling the anthrasil market.
Anthrasil Market Segment Performance And Emerging Opportunities
The anthrasil market covered in this report is segmented –
1) By Type: 60U, 100U
2) By Clinical Indication: Inhalational Anthrax, Anthrax Toxin Neutralization, Severe or Systemic Anthrax Infections, Prevention of Disease Progression in At-Risk Populations, Post-Exposure Prophylaxis (PEP)
3) By End-User: Hospital Pharmacy, Retail Pharmacy, Other End-Users
Anthrasil Market Trends Powering Strategic Industry Growth
Leading companies in the anthrasil market are concentrating on innovative vaccine development processes, such as cell-free filtrate technology, to boost efficacy, improve safety profiles, and address evolving bioterrorism threats. This cell-free filtrate technology utilizes non-living components from an avirulent strain of Bacillus anthracis, which helps reduce the risk of adverse reactions while effectively stimulating the immune system. For instance, in July 2023, Emergent BioSolutions Inc., a US-based biopharmaceutical company focused on developing vaccines and antibody therapeutics for infectious diseases, obtained U.S. Food and Drug Administration (FDA) approval for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), signifying a major advancement in anthrax vaccination efforts. CYFENDUS integrates an adjuvant called CPG7909, which enhances the immune response, potentially leading to more robust and rapid antibody production against Bacillus anthracis. The vaccine is derived from cell-free filtrates of an avirulent strain of B. anthracis, ensuring it contains no live or dead bacteria, which may decrease the risk of adverse reactions compared to traditional vaccines that include whole organisms.
Anthrasil Market Key Players: Which Companies Lead Industry Competition?
Major companies operating in the anthrasil market are Emergent BioSolutions Inc.
View The Full Anthrasil Market Report:
Anthrasil Market Regional Breakdown: Where Is Demand Concentrated?
North America was the largest region in the Anthrasil market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthrasil market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
